| Name | Title | Contact Details |
|---|
Cerebral is a mental health company dedicated to improving access to treatment for anxiety and depression.
Memorial Hospital at Gulfport is a not-for-profit medical complex in Gulfport, Mississippi, jointly owned by the City of Gulfport and Harrison County. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated Level II Trauma Center, two outpatient surgery centers, satellite outpatient diagnostic and rehabilitation centers and more than 95 Memorial Physician Clinics. Memorial offers several of the region`s most comprehensive clinical programs, such as emergency medicine; women and children services; orthopedic services; cardiovascular services; neurosciences and oncology. Additionally, Memorial provides medical specialties unique to the coast which include a Level III Neonatal ICU and Mississippi`s first nationally certified Primary Stroke Center. Memorial offers 3D imaging and advanced surgical techniques, including the robotic assisted Specialty Surgery System. Memorial is accredited by The Joint Commission, the Commission on Cancer, the College of American Pathologists and the American College of Radiology.
For more than 85 years, the Hendrick name has been the first name in healthcare in Abilene, Texas, and the Texas Midwest. As the first healthcare network to establish a true system of services, the Hendrick name reigns over a 522-bed medical center, a women’s center, rehabilitation hospital, cancer center and numerous other innovative services. Hendrick was the first hospital to permanently serve the Texas Midwest when its doors opened in 1924. During the Great Depression, it was the first hospital people of the Big Country area rallied behind to keep the doors open when money was scarce. Mr. and Mrs. Thomas Hendrick, for whom the institution was named, made the first major financial gift to the hospital. Through the years it has been the first in the area to offer specialized services, creating departments to fill needs such as physical medicine, nuclear medicine, spiritual care and much more.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
As a world-class academic and health care system, Duke Health strives to transform medicine and health locally and globally through innovative scientific research, rapid translation of breakthrough discoveries, educating future clinical and scientific leaders, advocating and practicing evidence-based medicine to improve community health, and leading efforts to eliminate health inequalities.